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The association between myocardial infarction (MI) and future risk of incident cancer is scarcely 
investigated. Therefore, we aimed to study the risk of cancer after a first time MI in a large cohort 
recruited from a general population. Participants in a large population-based study without a 
previous history of MI or cancer (n=28763) were included and followed from baseline to date of 
cancer, death, migration or study end. Crude incidence rates (IRs) and hazard ratios (HRs) for 
cancer after MI were calculated. During a median follow-up of 15.7 years, 1747 subjects 
developed incident MI, and of these, 146 suffered from a subsequent cancer. In the multivariable-
adjusted model (adjusted for age, sex, BMI, systolic blood pressure, diabetes mellitus, HDL 
cholesterol, smoking, physical activity and education level), MI patients had 46% (HR 1.46; 95% 
CI: 1.21-1.77) higher hazard ratio of cancer compared to those without MI. The increased cancer 
incidence was highest during the first 6 months after the MI, with a 2.2-fold higher HR (2.15; 
95% CI: 1.29-3.58) compared with subjects without MI. After a 2-year period without higher 
incidence rate, MI patients displayed 60% (HR 1.60; 95% CI: 1.27-2.03) higher HR of future 
cancer more than 3 years after the event. The increased incidence rates were higher in women 
than men. Patients with MI had a higher short- and long-term incidence rate of cancer compared 
to subjects without MI. Our findings suggest that occult cancer and shared risk factors of MI and 
cancer may partly explain the association. 
 




Myocardial infarction (MI) and cancer are major causes of morbidity and mortality 
worldwide [1]. While there is limited knowledge regarding the relation between MI and cancer, 
previous registry-based cohorts of MI patients suggest that these patients are at a modest 5-8 % 
increased risk of cancer [2, 3]. Occult cancer may induce a prothrombotic phenotype [4] of which 
MI may be the first sign [5]. An association between MI and subsequent cancer risk may be due 
to shared risk factors (e.g. smoking [6], obesity [7, 8], and low physical activity [9]), a 
consequence of MI diagnosis and treatment (e.g. surveillance bias), or an MI-related (e.g. chronic 
inflammation) impact on cancer risk. Growing evidence suggests that MI and cancer share the 
same molecular pathways of disease development and progression [10, 11] and that chronic 
inflammation plays a pivotal role in both carcinogenesis and atherosclerosis [12, 13]. 
The risk of cancer after MI has been scarcely investigated, and information on this topic is 
mainly derived from registry-based case-cohort studies. Due to lack of information about 
possible confounders like body mass index (BMI) and smoking [3, 2], exclusion of patients that 
died during the first year after MI [3], and limited validation of exposures and outcomes [3, 2], 
the results of these studies should be interpreted with caution. Moreover, the time since the MI 
diagnosis may influence the cancer risk. Therefore, we aimed to investigate the risk of cancer 
after a first episode of MI using a large population-based cohort with validated information about 







We recruited study participants from the fourth, fifth and sixth survey of the Tromsø Study, 
conducted in 1994-95, 2001 and 2007-08, respectively. The Tromsø Study is a single-center, 
prospective, population-based study, with repeated health surveys of the inhabitants in Tromsø, 
Norway. The overall attendance proportion was high; 77 % in the fourth, 78 % in the fifth and 66 
% in the sixth survey. In total, 30 586 unique subjects aged 25 to 97 years participated in at least 
one of the three surveys. A detailed description of the Tromsø Study has previously been 
published elsewhere [14]. The regional committee for research ethics in Northern-Norway 
approved the study, and all subjects gave their informed written consent. Subjects who did not 
consent to medical research (n = 225), and subjects not officially registered as inhabitants of the 
municipality of Tromsø at the date of study enrollment (n = 49) were excluded. Furthermore, 
subjects with a history of cancer (n = 815) or MI (n = 734) before baseline were excluded. 
Consequently, 28 763 subjects were included in the study, and followed from the date of 
enrollment to the end of follow up, the 31st of December 2010 (Fig. 1).  
 
Baseline measurements 
Baseline information about study participants was collected by physical examination, blood 
samples and self-administrated questionnaires. Systolic and diastolic blood pressure were 
measured three times with 1-minute intervals with an automatic device (Dinamap Vital Signs 
Monitor, 1846; Critikon Inc., Tampa, FL, USA) in a sitting position after 2 minutes of rest, and 
defined as the mean of the last two readings. Non-fasting blood samples were collected from an 
antecubital vein, serum prepared by centrifugation after 1-hour respite at room temperature and 
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analyzed at the Department of Clinical Chemistry, University Hospital of North Norway, 
Tromsø, Norway. Serum total cholesterol was analyzed by an enzymatic colorimetric method 
using a commercially available kit (CHOD-PAP, Boehringer-Mannheim, Mannheim, Germany). 
Serum HDL-cholesterol was measured after precipitation of lower-density lipoproteins with 
heparin and manganese chloride. Height and weight were measured with subjects wearing light 
clothes and no shoes. BMI was calculated as weight in kilograms divided by the square of height 
in meters (kg/m2). Subjects were classified as obese (BMI ≥ 30 kg/m2) according to the World 
Health Organization definition [15]. Hypertension was defined as mean systolic blood pressure ≥ 
140 mm Hg, mean diastolic blood pressure ≥ 90 mm Hg, or self-reported use of blood pressure-
lowering drugs. Hypercholesterolemia was classified as total serum cholesterol ≥ 6.5 mmol/L or 
self-reported use of lipid lowering drugs. Information on smoking status, family history of MI, 
diabetes mellitus, physical activity and education level was collected from a self-administrated 
questionnaire. Smoking status was assessed as self-reported daily smoking of cigarettes cigar or 
pipe (yes/no). Physical activity was classified as more than 1 hour of moderate or hard physical 
activity per week (yes/no), and education was dichotomized into a variable stating less or more 
than 10 years of education (yes/no). The proportion of missing data in our study was low (<3 %), 
and subjects with missing values were found to be similar to subjects included in the analysis 
with regards to clinically relevant parameters.  
Assessment of myocardial infarction events 
Based on data from hospital and out-of hospital medical records, autopsy records, and death 
certificates, an independent end-point committee validated hospitalized and out-of-hospital 
events of myocardial infarction. Further, the Norwegian national 11-digit identification number 
allowed linkage to national and local diagnosis registries. Cases of possible incident myocardial 
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infarction were identified by linkage to the hospital discharge diagnosis registry at the University 
Hospital of North Norway with a broad search for the International Classification of Diseases 
(ICD), ICD 8 codes 410–414, 427, 795–796 in the period 1969–1979 (in order to exclude 
prevalent MIs before inclusion), ICD 9 codes 410–414, 427.5, 798 and 799 in the period 1980–
98, and thereafter ICD 10 codes I20–I25, I46, R96, R98 and R99. The hospital medical records 
were retrieved for case validation. Modified World Health Organization MONICA (Monitoring 
of Trends and Determinants in Cardiovascular Disease)/MORGAM (MONICA Risk, Genetics, 
Archiving and Monograph Project) criteria for MI were used. MI was defined by one of the 
following sets of conditions: a) typical, atypical or inadequately described symptoms + a definite 
new infarction in ECG recordings, b) typical symptoms + significantly higher myocardial 
enzyme and/or troponin levels, c) atypical or inadequately described symptoms + significantly 
higher myocardial enzyme and/or troponin levels + a probable new infarction in ECG recordings, 
and d) post-mortem evidence of recent MI or thrombosis.[16]. Further, linkage to the National 
Causes of Death Registry at Statistics Norway allowed identification of fatal incident cases of MI 
that occurred as out-of-hospital deaths, including deaths that occurred outside of Tromsø. 
Information from the death certificates was used to collect relevant information on the MI events 
from additional sources such as autopsy reports and records from nursing homes, ambulance 
services, and general practitioners. 
 
Registry of cancer events 
Cancer events were identified by linkage to the Cancer Registry of Norway by use of the unique 
national civil registration numbers of the study participants.  Identification of events in the 
Cancer Registry were obtained with the International Classification of Disease, Revision 7 (ICD 
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7) codes 140-205. Subjects with non-melanoma skin tumors (ICD 7 191.0-191.9) were classified 
as cancer-free. Cancer registration is mandatory by law in Norway and the Cancer Registry is 
considered complete and valid. The Cancer Registry provides information about date of cancer 
diagnosis, location of the disease, cancer stage (localized, regional, distant or unknown) 
histological grade and initial treatment. Evaluation of the registry data quality showed 98.8 % 
completeness. For all sites combined, 93.8% of the cases were morphologically verified, 0.9% 
were registered on the basis of a death certificate only, and 2.2% were registered with primary 
site unknown. [17].  
 
Statistical Analysis 
Statistical analyses were performed using STATA version 14.0 (Stata corporation, College 
Station, TX, USA). Crude incidence rates (IRs) of cancer were calculated and expressed as 
number of events per 1 000 person-years at risk. For each participant, non-exposed and exposed 
person-years of follow-up were counted from the date of enrollment to the date of an incident 
diagnosis of cancer, the date the participant died or moved from the municipality, or until the end 
of the study period, 31st of December 2010, whichever came first. Subjects who died (2938) or 
moved (4566) from the municipality during follow-up were censored at the date of death or 
migration, respectively. MI was treated as a time-varying co-variate. Subjects who developed MI 
during the study period contributed with non-exposed person-time from the inclusion date to the 
date of a diagnosis of MI, and then with exposed person-time from the date of MI onward. 
Consequently, subjects developing cancer before MI contributed with cancer events in the non-
exposed category. 
Cox proportional hazard regression models were used to estimate age- and sex-adjusted 
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and multivariable adjusted hazard ratios (HRs) with 95 % confidence intervals (CI) for cancer 
after MI. MI was entered as a time-varying exposure in the Cox-model. Thus, 28 740 subjects 
contributed with 346 684 observation periods. Age was used as a time-scale in the Cox model, 
with the age of the participants at study enrollment defined as entry time and age at cancer-event 
or censoring event (i.e. death, migration, or the date of study end) as exit-time. The HRs were 
estimated according to different time intervals after the MI using the stsplit function in Stata (<6 
months, 6 months-<1 year, 1-3 years, and more than 3 years), and adjusted for potential 
confounders in three different models. Model 1 was adjusted for sex and age (as time scale), 
while Model 2 was additionally adjusted for BMI. Model 3 was adjusted for age (as time scale), 
sex, BMI (as a continuous variable), diabetes mellitus, current smoking (yes/no), systolic blood 
pressure, HDL-cholesterol, physical activity and education level. Since the median age of first MI 
is known to be approximately 10 years higher in women than in men [18], sex-specific analyses 
were conducted. Missing data were handled using available-case analyses. The proportional 
hazards assumption was tested using Schoenfeld residuals and was not violated.  
Results 
 
In total, 1 747 (6.1 %) subjects experienced a first-time MI, and of these 146 (8.4 %) developed 
subsequent cancer during a median follow up of 15.7 years. Baseline characteristics of the study 
participants with and without MI are shown in Table 1. Subjects who developed MI had higher 
mean age and BMI, and included higher proportions of men, smokers, and subjects with 
hypertension, hypercholesterolemia and diabetes mellitus. The proportions of physically active 
subjects and subjects with more than 10 years of education were lower among those who 
developed MI during follow up (Table 1). 
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 The distributions of different cancer sites among patients with MI are shown in table 2. 
The most frequent types of cancers were colorectal cancer (22 %), prostate cancer (22 %) and 
lung cancer (16 %) (Table 2).  
 The incidence rates and HRs for cancer are shown in table 3. In subjects without MI, 2 
470 cancer events were identified during 340 216 person-years (IR 7.3 per 1 000 person-years) of 
follow up, whereas there were 146 cancer events during 6 468 person-years of follow-up in 
subjects diagnosed with MI (IR 22.6 per 1 000 person-years). Overall, MI was associated with a 
46 % (multivariable adjusted HR 1.46; 95% CI: 1.21-1.77) increased hazard ratio of cancer. In 
sex specific analyses, women had higher incidence rate estimates for cancer by MI than men, but 
the confidence intervals overlapped (Table 3).  In sub group-analyses by tobacco-associated 
cancers, the incidence rate estimates for tobacco-associated and not-tobacco-associated cancers 
were similar for both groups (Supplementary Table 1). Other risk factors such as male sex, high 
BMI, increased systolic blood pressure, diabetes mellitus and current smoking were all associated 
with increased risk of cancer in our study population. Contrary, higher education and physical 
activity had a protective effect on the risk of cancer (Supplementary Table 2). 
The incidence of cancer in subjects with MI changed over time after the MI event (Table 
4). The highest incidence was found for the first 6 months after the MI diagnosis (IR 29.0 per 1 
000 person-years). The absolute risk increase was 21.7 additional events of cancer per 1 000 
persons the first 6 months after diagnosis compared with subjects without MI (Table 4). The 
hazard ratio of cancer was 2.2-fold higher the first six months after MI (HR 2.15; 95% CI: 1.29-
3.58) compared to subjects without MI, followed by a time period from 6 months to 3 years after 
MI without any increased cancer incidence rate (Table 4). In the period more than 3 years after 
MI, the hazard ratio of cancer was 60 % (HR 1.60; 95% CI: 1.27-2.03) higher compared to 
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subjects without MI. The short- and long-term incidence rate estimates for cancer by MI were 




In our prospective cohort of almost 29 000 subjects followed for 16 years, subjects who 
developed MI had 46 % higher hazard ratio of cancer compared to subjects without MI. The risk 
of incident cancer by MI displayed a biphasic risk pattern. During the first 6 months after the MI 
diagnosis, a transient 2.2-fold increased hazard ratio of cancer was accompanied by a time-period 
from 6 months to 3 years after MI without any association between MI and cancer. A secondary 
phase with a 60 % increased incident rate of incident cancer was observed more than 3 years after 
the MI diagnosis. The hazard ratio of cancer by MI was higher in women than in men. 
Few studies have investigated the association between MI and future risk of cancer.  Two 
independent registry-based cohorts of coronary heart disease (CHD) patients have suggested that 
MI patients are at modest increased risk of cancer, particularly of smoking-related cancers [3, 2]. 
Patients with ischemic syndromes in Stockholm county (n = 63 921) had an 8 % higher risk of 
cancer, particularly of smoking-related cancer in which the risk was 16 %, and 62 % increased in 
men and women, respectively [2]. Similarly, a Danish registry-based cohort of one-year survivors 
of MI (n = 96 891) showed an overall 5% increased risk of cancer, and an 8% and 36% increased 
risk of smoking-related cancer in men and women, respectively [3]. In accordance with these 
studies, we observed that women had an apparently higher short- and long-term incidence rate of 
cancer after MI compared to men. Although sex-dependent mechanisms could possibly explain 
the association, it is likely that the apparently  increased hazard ratio in women is partly 
explained by the lower baseline risk of MI in women compared to men, as the absolute risk 
increase (difference in incidence rates) of cancer by MI was similar in men and women (Table 3 
and Table 4). 
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In our study, the hazard ratio of cancer was particularly high during the first six months 
after the MI diagnosis. Surveillance bias may to some extent explain the immediate transient 
increase in incidence rate of cancer after MI.  First, patients hospitalized for MI are subjected to 
in-depth examination and testing that may lead to earlier detection of cancer. Second, aggressive 
antithrombotic therapy in the initial phase of MI may cause an asymptomatic tumor to present 
with bleeding with subsequent detection. Third, surveillance bias is expected to be accompanied 
by an apparent lowering of the cancer incidence after the initial period due to earlier diagnosis of 
cancer in subjects that are surveilled and treated for MI. Another possible explanation could be 
the presence of occult cancer at the time of MI.  Occult cancer may provide a prothrombotic 
phenotype [4] of which MI may be the first sign. Occult cancer is associated with increased MI 
risk [5], and the risk of MI is particularly high the first 6 months after cancer diagnosis [19]. 
The observed 60% increased hazard ratio of cancer occurring more than 3 years after the 
MI event suggests that other mechanisms than surveillance bias and occult cancer are involved 
for the long-term risk.  For instance, MI and cancer share common risk factors such as smoking 
[6], obesity [8, 7], and low physical activity [9]. Both environmental and behavioral risk factors 
have atherogenic and carcinogenic effects, which may give rise to an increased risk of cancer in 
individuals with atherosclerotic diseases [20]. The most apparent risk factor is smoking, which 
increases the risk of several types of cancer and MI [21, 22, 6]. Some previous studies have 
attributed the observed increased incidence of cancer after MI to tobacco-related cancers [2, 3], 
and in a study of almost 100 000 one-year-survivors of MI there was no increased risk of cancers 
that were not related to smoking [3]. On the other hand, a registry-based follow-up study reported 
an increased incidence rate of arterial thrombosis in cancer patients, and the incidence rate was 
not exclusively higher in cancers associated with smoking [19]. In our study, adjustments for 
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established shared risk factors such as smoking, obesity and physical activity in our multivariable 
model did not influence the relation between MI and cancer. Furthermore, the hazard ratios were 
similar for tobacco-associated and not tobacco-associated cancer. Thus, our findings suggest that 
these factors could not explain the long-term cancer risk. 
Even though MI and cancer share some molecular pathways of disease development and 
progression [10, 11], the distinct mechanisms behind the observed association between MI and 
cancer are unclear. Cancer patients exhibit a prothrombotic phenotype attributed to the presence 
of circulating procoagulants (e.g. tissue factor) liberated from cancer cells and macrophages, an 
increased turnover and activity of platelets, damage to the endothelium, and abnormalities of the 
blood flow [4, 23]. This implies that occult cancer may contribute to the short-term risk of cancer 
after MI.  A previous case-control study has suggested a link between hypercoagulability in 
cancer and risk of MI [5], but there is conflicting data, regarding the increased risk of MI in 
thrombophilia [1, 24-29]. However, it is possible that inflammation could be an important link 
between cancer and MI. Studies have shown that inflammation may initiate and increase 
atherosclerosis, evoke MI [13, 30], and be carcinogenic [31, 32, 12]. The hypothesis of 
inflammation as a link is supported by studies showing an increased risk of MI in cancers 
associated with inflammation (e.g. colorectal cancer) [5, 33, 2, 34]. However, due to the few 
studies in this field, the causal mechanism for the association remains unsettled.  
Secondary prevention for MI may influence the risk of cancer. Prolonged aspirin 
treatment have shown reduced mortality of several common cancers [35]. Furthermore, daily 
treatment with aspirin (six studies, n = 35 535) reduced the risk of incident cancer from 3 years 
onward [36]. Thus, treatment with aspirin would be expected to weaken the association between 
MI and long-term cancer [35-37]. Studies on statin treatment and future development of cancer 
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are inconsistent: Some studies have observed that use of statins may reduce both the risk of 
developing cancer and the rates of cancer-specific mortality for several cancer types [38-40]. 
However, other studies indicated that statins might increase the risk of cancer [41-43]. One main 
objection regarding many statin trials is the short study length with 5 years at most [43], and it 
may take many years before exposure to carcinogenic substances results in cancer. The 
prescription of statins started in the middle of the 1990s and quickly became a standard treatment 
for patients with MI. Thus, most of the patients with MI in the present study have been prescribed 
statins. Unfortunately, we are not able to adjust for statin or aspirin use due to incomplete 
registration in the Tromsø Study. 
The clinical implications for our findings are uncertain. The socioeconomic cost and 
individual suffering of a screening program for cancer in patients with MI would probably 
surpass the benefits of early detection and improved prognosis since a major proportion of 
cancers in our study was detected within 6 months without a screening program. However, the 
long-term increased incidence rate of cancer after MI suggests that MI itself, or drugs used for 
secondary prevention of MI, may convey development of cancer or, even more likely, that the 
two conditions share genetic or environmental risk factors. Accordingly, the impact of shared risk 
factors was apparently stronger for cancer risk in MI (60 % increased risk more than 3 years after 
MI) than in venous thromboembolism (30 % increased risk) [44, 45]. Thus, it is warranted to 
identify predictors of cancer in MI patients in order to identify subjects at high cancer risk, and to 
unveil modifiable risk factors susceptible for intervention in order to reduce the incidence of 
cancer in MI patients. 
The main strengths of our study are the prospective design with a long follow-up period, 
the large number of participants recruited from a general population, thoroughly validated events 
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of both MI and cancer and the possibility to adjust for lifestyle factors as potential confounders. 
As most known shared risk factors for MI and cancer are modifiable, the risk profile may change 
during follow-up. To minimize this possible misclassification, we updated the baseline 
information with repeated measurements in the two latest Tromsø surveys. Due to a limited 
number of cancer events, we had limited statistical power to investigate the risk of specific cancer 
types or the cancer stage at the time of diagnosis. Although our model included several potential 
confounders, residual confounding could still be present, and a possibility to adjust for 
medication and inflammatory markers would have strengthened the study.  
In conclusion, subjects who developed MI had a higher short- and long-term hazard ratio 
of cancer compared to those without MI.  The long-term increased incidence rate of cancer after 
MI may be explained by shared genetic or environmental risk factors other than smoking, 
obesity, and low physical activity. Future studies are warranted to identify predictors and 
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Figure legends  
Figure 1 Inclusion of study participants from the fourth (1994–1995), fifth (2001–2002) and sixth (2007–




Table 1. Baseline Characteristics of Participants without and with Myocardial Infarction 
(n=28763). The Tromsø Study 1994-2010 
 No MI (n = 27016) MI (n = 1747) 
Age, yrs. 45 ± 14 62 ± 13 
Sex (male) 46.1 (12 467) 62.0 (1 083) 
BMI (kg/m2) 25.2 ± 3.9 26.6 ± 4.1 
Total cholesterol (mmol/L) 5.89 ± 1.27 6.92 ± 1.27 
HDL cholesterol (mmol/L) 1.50 ± 0.41 1.41 ± 0.40 
Triglycerides (mmol/L) 1.23 (0.86, 1.85) 1.65 (1.17, 2.38) 
Systolic blood pressure (mmHg) 132 ± 19  152 ± 24 
Diastolic blood pressure (mmHg) 77 ± 12 87 ± 14 
Hypertensiona 31.1 (8 397) 70.4 (1 230) 
Hypercholesterolemiab 30.1 (8 125) 62.5 (1 092) 
Smoking c 35.8 (9 666) 42.5 (742) 
Physical activity d 33.6 (9 082) 20.7 (361) 
Educatione 29.3 (7 918) 12.1 (212) 
Self-reported diabetes mellitus 1.4 (378) 6.4 (112) 
Values are % (n), mean ± SD or median (25th and 75th percentile) (for triglycerides) . BMI 
indicates body mass index and MI, myocardial infarction  
aMean systolic/diastolic blood pressure ≥140/≥90 mm Hg, use of blood pressure-lowering drugs, 
or self-reported hypertension. 
bTotal cholesterol ≥ 6.5 mmol/L, use of lipid-lowering drugs, or self-reported 
hypercholesterolemia 
cSelf-reported daily smoking, yes/no 
d≥ 1 hours of moderate or hard physical activity per week, yes/no 
e> 10 years of education 
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Table 2. Site of Cancer Diagnosis after Myocardial Infarction sorted in descending order of 
frequency. The Tromsø Study 1994-2010 
Cancer sites % (n) 
Colorectal cancer 21.9 (32) 
Prostatic cancer 21.9 (32) 
Lung cancer 16.4 (24) 
Hematological cancer 6.2 (9) 
Urinary bladder cancer 5.5 (8) 
Gastric cancer 3.4 (5) 
Kidney cancer 3.4 (5) 
Pancreatic cancer 3.4 (5) 
Lymphatic cancer 2.7 (4) 
ENT cancer 2.1 (3) 
Breast cancer 2.1 (3) 
CNS/PNS cancer 1.4 (2) 
Liver cancer 1.4 (2) 
Esophagus cancer 0.7 (1) 
Gynecological cancer 0.7 (1) 
Other cancer sites 6.8 (10) 
Total cancer events 100 (146) 
 
Values are % (n). CNS/PNS, indicates central nervous system/peripheral nervous system, and 
ENT, ear, nose and throat
Table 3 Sex-Stratified Incidence Rates and Hazard Ratios for Cancer after Myocardial Infarction. The Tromsø Study 1994-2010 
  Person-years Cancer events Crude IR (95% 
CI)a 
HR (95% CI)b HR (95% CI)bc HR (95% CI)bcd 
Total       
No MI 340216 2470 7.3 (7.0-7.6) Reference Reference Reference 
MI 6468 146 22.6 (19.2-26.5) 1.41 (1.19-1.67) 1.43 (1.21-1.70) 1.46 (1.21-1.77) 
Women       
No MI 182846 1272 7.0 (6.6-7.3) Reference Reference Reference 
MI 2215 46 20.8 (15.6-27.7) 1.48 (1.09-1.99) 1.50 (1.11-2.02) 1.65 (1.19-2.29) 
Men       
No MI 157371 1198 7.6 (7.2-8.1) Reference Reference Reference 
MI 4253 100 23.5 (19.3-28.6) 1.30 (1.06-1.60) 1.31 (1.07-1.61) 1.29 (1.02-1.62) 
CI indicates confidence interval; MI, myocardial infarction; IR, incidence rate and HR, hazard ratio 
aPer 1000 persons-years 
bAdjusted for age (as time scale) and sex-adjusted 
cAdjusted for body mass index. 
dAdjusted for systolic blood pressure, diabetes mellitus, HDL, smoking, physical activity, and education level 





Crude IR (95% CI)a HR (95% CI)b HR (95% CI)bc HR (95% CI)bcd 




2470 7.3 (7.0-7.6) Reference  Reference Reference 
< 6 months after MI 552 16 29.0 (17.8-47.4) 1.94 (1.18-3.17) 1.96 (1.20-3.21) 2.15 (1.29-3.58) 
6 months - <1 year after MI 514 8 15.6 (7.8-31.1) 1.04 (0.52-2.09) 1.05 (0.53-2.11) 0.92 (0.41-2.06) 
1-3 years after MI 1747 28 16.0 (11.1-23.2) 1.05 (0.72-1.52) 1.06 (0.73-1.54) 1.13 (0.76-1.68) 
> 3 years after MI 3655 94 25.7 (21.0-31.5) 1.54 (1.25-1.90) 1.57 (1.27-1.93) 1.60 (1.27-2.03) 




1272 7.0 (6.6-7.3) Reference  Reference Reference 
< 6 months after MI 195 7 35.8 (17.1-75.2) 2.66 (1.26-5.6) 2.69 (1.28-5.67) 3.20 (1.52-6.76) 
6 months - <1 year after MI 181 2 11.1 (2.8-44.2) 0.81 (0.20-3.23) 0.82 (0.20-3.28) 0.99 (0.25-3.95) 
1-3 years after MI 608 8 13.2 (6.6-26.3) 0.95 (0.47-1.90) 0.96 (0.48-1.93) 1.17 (0.58-2.35) 










Crude IR (95% CI)* HR (95% CI)† HR (95% CI)†! HR (95% CI)†!‡ 
Men       
No MI 157371 1198 7.6 (7.2-8.1) Reference  Reference Reference 
< 6 months after MI 356 9 25.3 (13.1-48.6) 1.55 (0.80-2.99) 1.56 (0.81-3.00) 1.58 (0.78-3.17) 
6 months - <1 year after MI 333 6 18.0 (8.1-40.1) 1.09 (0.49-2.42) 1.09 (0.49-2.44) 0.83 (0.31-2.23) 
1-3 years after MI 1139 20 17.6 (11.3-27.2) 1.05 (0.67-1.63) 1.05 (0.68-1.64) 1.04 (0.64-1.68) 
> 3 years after MI 2424 65 26.8 (21.0-34.2) 1.41 (1.09-1.81) 1.41 (1.10-1.82) 1.42 (1.07-1.89) 
CI indicates confidence interval; MI, myocardial infarction; IR, incidence rate and HR, hazard ratio 
aPer 1000 persons-years 
bAdjusted for age (as time scale) and sex-adjusted 
cAdjusted for body mass index 
dAdjusted for systolic blood pressure, diabetes mellitus, HDL, smoking, physical activity, and education level
 
